Teplinovivint-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemETeplinovivintCat.No.:HY-137454CASNo.:1428064-91-8分?式:C??H??N?O?分?量:442.51作?靶點(diǎn):Wnt;β-catenin作?通路:StemCell/Wnt儲存?式:Powder-20°C3yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:83.33mg/mL(188.31mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.2598mL11.2992mL22.5984mL5mM0.4520mL2.2598mL4.5197mL10mM0.2260mL1.1299mL2.2598mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(4.70mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:2.08mg/mL(4.70mM);Suspendedsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性Teplinovivint?種有效的wnt/β-catenin信號通路抑制劑。Teplinovivint具有抗炎活性，具有?于肌腱病研究的潛?。IC50&TargetWnt體外研究Teplinovivint(compound175;0.0003-10μM)inhibitsWnt/p-cateninactivityinhumancolorectalcancecellline(SW480)inadose-dependentmanner(EC50=152.9nM)[1].TeplinovivintinhibitsSW480cells(EC50=25nM)andprimaryhumanmesenchymalstemcells(hMSCs;EC50=10.377μM)[1].Teplinovivint(5.8,10.8,21.7,41.7,83.3,166.6,333.3,750nM)inducedtheexpressionofSCXA,TenacinCandTenomodulin,inadose-dependentmannerwithanEC50between139-189nM[1].體內(nèi)研究Teplinovivint(compound175;10mg/ml;oncedailyfor21daysviatopicalapplication)causesameliorationofinflammationaswellastendondegeneration.Teplinovivintresultsinadecreaseofaninflammatoryplasmabiomarker,KC/GROintheCollagenase-inducedTendonInjuryModel[1].Teplinovivint(1mg/mlwith1%BA)hasaTmaxof1hoursinplasma[1].REFERENCES[1].VishalDESHMUKH,etal.Methodsofusingindazole-3-carboxamidesandtheiruseaswnt/b-cateninsignalingpathwayinhibitors.WO2018075858A1.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseo